Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a hormone patch ease suicidal thoughts during periods?

NCT ID NCT06191289

Symptom relief Sponsor: University of Illinois at Chicago Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at whether a transdermal estrogen patch, applied for two weeks around the menstrual period, could reduce suicidal thoughts in women who had recently experienced them. Eleven women participated, and the study compared the estrogen patch to a placebo patch. The goal was to see if boosting estrogen levels could help stabilize mood and reduce suicidal ideation during a vulnerable time of the month.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
transdermal estradiol (estrogen patch)
What this could lead to
If it works, this could point toward a short-term hormone treatment to ease suicidal thoughts during the menstrual period.
What could go wrong
This was a very small, early-phase study that was terminated early, so results are limited. The treatment is only for a specific time window and may not help everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

11 people

The number who actually took part.

Started

Mar 2024

Finished

Dec 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

20 to 40 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Ability to adhere to medication regimen * Speaks English * Assigned female at birth with intact ovaries * Premenopausal * Normal menstrual cycles between 24-32 days * Under current care of an outpatient mental health provider with visits occurring at least once every 3 months. * At least 1 year postpartum. * Willing to use a barrier method of birth control during the study. * Normal weight (BMI between 18-29) * Must report at least some recent suicidal ideation (in the past month) at the time of recruitment. * Must be categorized as having acceptably low imminent risk for suicidal crisis/attempt by a licensed clinical psychologist utilizing evidence-based clinical and research guidelines for imminent suicide risk management. Exclusion Criteria: * Must not be pregnant, breastfeeding, or trying to become pregnant. * Must not be taking any form of exogenous hormones or hormonal intrauterine device, and must have ended previous use of hormonal preparations at least one month prior to the study. * Must not have a personal history of any chronic medical condition, including but not limited to metabolic or autoimmune disease, epilepsy, endometriosis, cancer, diabetes, cardiovascular, gastrointestinal, hepatic, renal, or pulmonary disease, and no personal or first degree family history of thromboembolic events. * Any current cigarette smoking is exclusionary. * Must not report a history of clinical diagnosis or treatment for postpartum depression or premenstrual dysphoric disorder (Note: Premenstrual Dysphoric - - - Disorder diagnosis must have been made based on prospective daily ratings). * Must not report any history of manic episode, any history of psychotic symptoms, or current substance use disorder.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Suicide are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Suicide

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Suicide

Contacts and locations

Locations

  • University of Illinois Neuropsychiatric Institute

    Chicago, Illinois, 60612, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.